OpenScience.ink

3 weeks ago • Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Lower risks of falls and hip fractures with semaglutide and tirzepatide compared to DPP-4 inhibitors in older adults with type 2 diabetesLower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.

🎖️ Top 10% Journal

3 weeks ago • Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Effects of Glucagon-like Peptide-1 Drugs in Parkinson's Disease: A Meta-AnalysisGlucagon-like peptide-1 agonists in Parkinson's disease: a meta-analysis.

📖 Top 30% Journal

3 weeks ago • Handbook of experimental pharmacology

TAAR1 as a possible new target instead of GLP-1 for diabetes and obesity drugsTAAR1 as a Potential Alternate Molecular Target to GLP-1 for Novel Anti-diabetic, Anti-obesity Medications.

📖 Top 20% Journal

3 weeks ago • Journal of translational medicine

Breaking the cycle between unhealthy fat tissue and inflammation: a new approach to inflammatory diseaseDisrupting the adiposopathy-inflammation loop: a translational immunometabolic framework for inflammatory disease.

🥉 Top 5% Journal

3 weeks ago • Surgical endoscopy

Stopping a diabetes drug for two weeks around surgery and its link to leftover stomach contents during upper digestive tract examsEffect of two-week perioperative glucagon-like peptide-1 receptor agonist interruption on retained gastric contents during esophagogastroduodenoscopy: a retrospective, observational study.

📖 Top 20% Journal

3 weeks ago • Journal of obesity & metabolic syndrome

Obesity in Adults with Type 1 DiabetesObesity in Adults with Type 1 Diabetes Mellitus.

🥉 Top 5% Journal

3 weeks ago • Advances in therapy

Using GLP-1 Receptor Agonists to Treat Obesity and Type 2 Diabetes in Older Adults: Important Factors to ConsiderSpecial Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.

📖 Top 20% Journal

3 weeks ago • Childhood obesity (Print)

How Caregivers’ Use of GLP-1 Medicines May Affect Family Food Habits and Children's Health BehaviorsBeyond the Individual: Family-Level Impacts of Caregiver GLP-1 Use on Food Environments and Child Health Behaviors.

📖 Top 30% Journal

3 weeks ago • Journal of obesity & metabolic syndrome

Drug Treatments for Fatty Liver Disease Linked to Metabolism in the Age of Obesity and Metabolic MedicinePharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.

🥉 Top 5% Journal

3 weeks ago • Bioorganic chemistry

Designing small molecules that activate the GLP-1 receptor using lead compoundsLead-guided prodrug development of small molecules as GLP-1R agonists.

📖 Top 30% Journal

3 weeks ago • Advances in therapy

Combined Use of Two Diabetes Drugs in People with Type 2 Diabetes and Heart DiseaseBeyond Single-Class Therapy: Real-World Combined Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.

📖 Top 20% Journal

3 weeks ago • Stem cell reports

GLP-1 influences bone marrow stem cell development through HIF-2-AKT signals and helps maintain spongy bone in steroid-related osteoporosisGLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis.

🥉 Top 5% Journal

4 weeks ago • NEJM catalyst innovations in care delivery

Expanding a Primary Care Weight Management Program Across the State to Improve Obesity CareBreaking Barriers in Obesity Care - Scaling a Primary Care Weight Management Program Statewide.

📖 Top 20% Journal

← prevpage 8 of 14next →

GLP-1 Therapies Research Papers